Search Within

Breast Medicine Service

Formats
  1. Journal Article (2206)
  2. Meeting Abstract (1680)
  3. Review (83)
  4. Book Section (69)
  5. Editorial (44)
  6. Conference Paper (28)
  7. Guidelines (27)
  8. Correspondence (16)
  9. Miscellaneous (12)
  10. Research Letter (11)
  11. Book Whole (5)
Groups
  1. Department of Medicine (4181)
  2. Solid Tumor Oncology Division (4181)
  3. Survivorship Research (2373)
  4. GSK Faculty (1516)
  5. Population Sciences Research Program (1369)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1144)

More Groups

People
  1. Clifford Hudis (906)
  2. Larry Norton (762)
  3. Mark Robson (684)
  4. Neal Rosen (427)
  5. Andrew Seidman (319)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (130)
  2. 2024 (195)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (828)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (170)
  4. Annals of Oncology (159)
  5. Clinical Cancer Research (132)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (880)
  2. American Association for Cancer Research (755)
  3. Springer (332)
  4. Elsevier Inc. (308)
  5. Oxford University Press (282)
  6. Nature Publishing Group (276)

More Publishers

Results (4181)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2
    Meeting Abstract

    Tung, N. M.; Robson, M. E.; Nanda, R.; Li, T.; Vinayak, S.; Shah, P. D.; Khoury, K.; Kimmick, G. G.; Santa-Maria, C. A.; Brufsky, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2- breast cancer (BC)
    Meeting Abstract

    Juric, D.; Patel, M. R.; Duska, L. R.; Jhaveri, K. L.; Henick, B. S.; Matulonis, U. A.; Munster, P. N.; Birrer, M. J.; Moore, K. N.; Curigliano, G.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC
    Meeting Abstract

    Andre, F.; Hamilton, E. P.; Loi, S.; Anders, C. K.; Schmid, P.; Stroyakovskiy, D.; Villanueva, R.; Pedrini, J. L.; Doval, D. C.; Zurawski, B.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • ETHAN: A phase II study comparing different endocrine therapies for male breast cancer
    Meeting Abstract

    Leone, J. P.; Ruddy, K. J.; Rashid, N.; Giordano, S. H.; Gupta, G. P.; Hilsenbeck, S. G.; Gucalp, A.; Walsh, E. M.; Sukumar, J. S.; Makhlin, I.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2-breast cancer (BC) cohorts of EV-202
    Meeting Abstract

    Giordano, A.; Awan, A. A. A.; Bruce, J. Y.; Rugo, H. S.; Diamond, J. R.; Novik, Y.; Baranda, J. C.; Muro, K.; Ono, M.; Nanda, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Patient factors associated with chemotherapy modifications: Results from the Optimal Breast Cancer Chemotherapy Dosing (OBCD) study
    Meeting Abstract

    Kantor, E.; Bhimani, J.; Gallagher, G. B.; Blinder, V. S.; Burganowski, R. P.; Griggs, J. J.; Kolevska, T.; Kroenke, C.; Laurent, C.; Liu, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Patient characteristics associated with primary prophylactic granulocyte colony-stimulating factor (G-CSF) use among women treated for early-stage breast cancer
    Meeting Abstract

    Gallagher, G. B.; O'Connell, K.; Bhimani, J.; Blinder, V. S.; Burganowski, R. P.; Griggs, J. J.; Kolevska, T.; Kroenke, C.; Laurent, C.; Liu, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors
    Meeting Abstract

    Sands, J.; Tolaney, S. M.; Ueno, N. T.; Spira, A. I.; Yamamoto, N.; Janjigian, Y. Y.; Naito, Y.; Damodaran, S.; Meric-Bernstam, F.; Modi, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Alignment of patient-clinician perspectives in triple-negative breast cancer (TNBC)
    Meeting Abstract

    Ackbarali, T.; Goins, C.; Walker, S.; Donahue, S.; Witt, J.; Vidal, G. A.; Traina, T. A.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HOPE: Harnessing olaparib, palbociclib, and endocrine therapy for BRCA1/2-associated HR+, HER2- metastatic breast cancer
    Meeting Abstract

    Shah, P. D.; Torres, A.; Aaron, M.; Narayan, V.; Knollman, H. M.; Bradbury, A. R.; DeMichele, A.; Robson, M. E.; Tung, N. M.; Domchek, S. M.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save